Central Maine Healthcare

Belkins
An integrated healthcare delivery system, Central Maine Healthcare (CMH) serves 400,000 people in the central, western, and mid-coast regions of the state. One flagship medical center, two rural, critical access hospitals and an extensive variety of primary and specialty care practices located in 14 communities throughout the region make up the CMH system. Central Maine Healthcare is focused on exceptional quality and patient access to care. Affiliated with Mass General Hospital in Boston, CMH provides Mainers the most innovative and current treatments available without having to leave their hometown. The Mass General affiliation gives CMH patients greater access to sub-specialty care in hematology/oncology, neurology, stroke, and trauma.

Related News

RESEARCH

ELI LILLY WINS FDA'S EMERGENCY NOD FOR COVID-19 ANTIBODY—BUT, THANKS TO MIXED DATA, IT'S LIMITED

Eli Lilly | November 11, 2020

news image

The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCeller...

Read More

UPADHYE CWIK LLP GUIDES ABOUT INNOVATIVE LEGAL PRACTICES ON PHARMACEUTICAL AND FDA ISSUES IN COVID-19 WORLD

Upadhye Cwik LLP | July 02, 2020

news image

The COVID-19 pandemic continues to turn the world upside down. And when upside down, the legal issues surrounding pharmaceuticals and the FDA become apparent. We identify a few areas that our law firm is working on for clients. Our patent work remains busy helping clients with rationalizing patent portfolios, conducting infringement-mapping exercises to find potential licensing revenues, and patent litigation to enforce patent rights. Interestingly we see some clients not cutting ...

Read More

RESEARCH

MODERNA AND MEDISON PHARMA COLLABORATE TO COMMERCIALIZE MODERNA'S COVID-19 VACCINE IN CENTRAL EASTERN EUROPE AND ISRAEL

Moderna | June 08, 2021

news image

Moderna, Inc., a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines, and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, announced today a new agreement to commercialize the Moderna COVID-19 Vaccine in Central Eastern Europe and Israel. Poland, Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia, and Herz...

Read More

PHARMA SALESFORCES BROUGHT TO A HALT AS CORONAVIRUS SHUTTERS ECONOMY

BioPharma Dive: | March 17, 2020

news image

Late last year, New Jersey drugmaker Amarin won a long-sought U.S. approval for its pill Vascepa, allowing the company to market the drug for reducing heart risk. It was a major milestone for the company, validating the decision to run a lengthy and expensive cardiovascular outcomes study, which had delivered positive results in 2018. Eager to sell the drug to a now much wider group of patients, Amarin doubled the number of sales representatives it employs to reach out to doctors and other healt...

Read More

RESEARCH

Eli Lilly | November 11, 2020

news image

ELI LILLY WINS FDA'S EMERGENCY NOD FOR COVID-19 ANTIBODY—BUT, THANKS TO MIXED DATA, IT'S LIMITED

The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCeller...

Read More

Upadhye Cwik LLP | July 02, 2020

news image

UPADHYE CWIK LLP GUIDES ABOUT INNOVATIVE LEGAL PRACTICES ON PHARMACEUTICAL AND FDA ISSUES IN COVID-19 WORLD

The COVID-19 pandemic continues to turn the world upside down. And when upside down, the legal issues surrounding pharmaceuticals and the FDA become apparent. We identify a few areas that our law firm is working on for clients. Our patent work remains busy helping clients with rationalizing patent portfolios, conducting infringement-mapping exercises to find potential licensing revenues, and patent litigation to enforce patent rights. Interestingly we see some clients not cutting ...

Read More

RESEARCH

Moderna | June 08, 2021

news image

MODERNA AND MEDISON PHARMA COLLABORATE TO COMMERCIALIZE MODERNA'S COVID-19 VACCINE IN CENTRAL EASTERN EUROPE AND ISRAEL

Moderna, Inc., a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines, and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, announced today a new agreement to commercialize the Moderna COVID-19 Vaccine in Central Eastern Europe and Israel. Poland, Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia, and Herz...

Read More

BioPharma Dive: | March 17, 2020

news image

PHARMA SALESFORCES BROUGHT TO A HALT AS CORONAVIRUS SHUTTERS ECONOMY

Late last year, New Jersey drugmaker Amarin won a long-sought U.S. approval for its pill Vascepa, allowing the company to market the drug for reducing heart risk. It was a major milestone for the company, validating the decision to run a lengthy and expensive cardiovascular outcomes study, which had delivered positive results in 2018. Eager to sell the drug to a now much wider group of patients, Amarin doubled the number of sales representatives it employs to reach out to doctors and other healt...

Read More